Case Report: Humanized Selective CD19CAR-T Treatment Induces MRD-Negative Remission in a Pediatric B-ALL Patient With Primary Resistance to Murine-Based CD19CAR-T Therapy

BACKGROUND: CD19 chimeric antigen receptor T cell (CD19CAR-T) has shown great potential to treat acute B cell lymphoblastic leukemia (B-ALL) and B cell lymphoma, and most of anti-CD19 scFv are derived from murine antibody sequences. However, about 10–20% of B-ALL patients exhibit primary resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Kai, Zhao, Yu, Wang, Xuan, Wang, Bin, Qin, Maoquan, Zhu, Guanghua, Wu, Huantong, Liu, Zhongfeng, Zheng, Xueling, Zheng, Huyong, Chen, Zhiguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786099/
https://www.ncbi.nlm.nih.gov/pubmed/33424835
http://dx.doi.org/10.3389/fimmu.2020.581116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786099/
https://www.ncbi.nlm.nih.gov/pubmed/33424835
http://dx.doi.org/10.3389/fimmu.2020.581116

Ejemplares similares